School of Medicine
Showing 71-80 of 680 Results
-
Carlos Castillo Passi
Postdoctoral Scholar, Radiological Sciences Laboratory
BioCarlos Castillo-Passi began his academic journey at Pontificia Universidad Catolica de Chile (PUC), where he earned both a degree and an MSc in Electrical Engineering in 2018. He then pursued a PhD in Biological and Medical Engineering through a joint program between PUC and King’s College London (KCL), completing it with maximum distinction in 2024. His research focused on the design of low-field cardiac MRI sequences using open-source MRI simulations. In 2023, his work on open-source MRI simulations was highlighted by the editor of Magnetic Resonance in Medicine (MRM). Furthermore, his application of this work to low-field cardiac MRI earned him the Early Career Award in Basic Science from the Society for Cardiovascular Magnetic Resonance (SCMR) in 2024. In addition to his research, Carlos is an active member of JuliaHealth, contributing to the development of high-performance, reproducible tools for health and medicine. In 2025, he joined Stanford University as a postdoctoral researcher, where he continues his work in cardiac MRI and open-source technologies.
-
Edwin Chang
Director, Small Animal Imaging Facility at Porter Drive, Rad/Molecular Imaging Program at Stanford
Current Role at StanfordDirector, SCI3@Porter or the Canary Core Preclinical Imaging Facility at Stanford
-
Stephanie Tzu-Ying Chang
Assistant Professor of Radiology
BioDr. Stephanie Chang is an Assistant Professor in Radiology at Stanford University School of Medicine, Section Chief in Abdominal Imaging, and Interim Director of Diagnostic Radiology in the Department of Radiology at VA Palo Alto.
Dr. Chang’s research program aims to utilize state-of-the-art diagnostic technology to non-invasively detect abdominal diseases that predispose or lead to cancer since the most beneficial and cost-effective cancer imaging occurs in the screening/early detection phase.
Currently, metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) are leading worldwide causes of end-stage liver disease and liver cancer (hepatocellular carcinoma, HCC). To determine the optimal multimodality screening and diagnostic pathway, Dr. Chang leads prospective research studies at VA Palo Alto comparing blood-based and imaging-based diagnostic tests – the Fibrosis-4 (FIB-4) Index, the Enhanced Liver Fibrosis (ELF) test, vibration controlled transient elastography (VCTE), ultrasound point shear wave elastography (US pSWE), and magnetic resonance imaging (MRI) elastography – among high-risk veterans with obesity and/or type 2 diabetes to compare relative performance and costs/benefits.
To improve detection of hepatocellular carcinoma (HCC) among patients with end-stage liver disease (cirrhosis), Dr. Chang also serves as a member of the VA National Radiology Working Group and radiology local site investigator at VA Palo Alto for a multicenter VA research study CSP #2023 PREventing liver cancer Mortality through Imaging with Ultrasound vs. MRI (PREMIUM STUDY) comparing US and MRI to determine optimal screening strategies for hepatocellular carcinoma.
While MRI has the overall highest sensitivity and specificity for many diseases and contains additional biological/prognostic information not obtainable via other imaging methods, the utility of MRI as a powerful non-invasive screening tool has been hampered by its limitations in access, time, and cost. Dr. Chang is interested in significantly shortening MRI exam times to accelerate MRI throughput, decrease patient discomfort, and reduce costs. To accomplish this goal, Dr. Chang is interested in improving pulse sequences to shorten MRI acquisition times while maintaining or increasing diagnostic quality. In addition, Dr. Chang is interested in novel MRI techniques to improve disease detection and staging.
